SUPERPARAMAGNETIC IRON-OXIDE PARTICLES AND POSITIVE ENHANCEMENT FOR MYOCARDIAL PERFUSION STUDIES ASSESSED BY SUBSECOND T-1-WEIGHTED MRI

被引:55
作者
CANET, E
REVEL, D
FORRAT, R
BALDYPORCHER, C
DELORGERIL, M
SEBBAG, L
VALLEE, JP
DIDIER, D
AMIEL, M
机构
[1] Laboratoire de Radiologie Expérimentale, URA CNRS 1216, Hôpital Cardiovasculaire et Pneumologique, 69394 Lyon Cedex 03, BP Lyon Montchat
[2] INSERM U63, Bron
[3] Siemens, Lyon
[4] Département de Radiologie, Hôpital Cantonal, Geneva
关键词
CONTRAST MEDIA; MAGNETIC RESONANCE (MR); CONTRAST ENHANCEMENT; IRON OXIDE; HEART PERFUSION; MYOCARDIAL ISCHEMIA;
D O I
10.1016/0730-725X(93)90241-5
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Superparamagnetic iron oxide particles (SPIOs) are usually referred to as T-2 MR contrast agents, reducing signal intensity (SI) on T-2-weighted MR images (negative enhancement). This study reports the original use of SPIOs as T-1-enhancing contrast agents, primarily assessed in vitro, and then applied to an in vivo investigation of a myocardial perfusion defect. Using a strongly T-1-weighted subsecond MR sequence with SPIOs intravenous (IV) bolus injection, MR imaging of myocardial vascularization after reperfusion was performed, on a dog model of coronary occlusion followed by reperfusion. Immediately after the intravenous bolus injection of 20 mu mol/kg of SPIOs, a positive signal intensity enhancement was observed respectively, in the right and left ventricular cavity and in the nonischemic left myocardium. Moreover, compared to normal myocardium, the remaining ischemic myocardial region (anterior wall of the left ventricle) appeared as a lower and delayed SI enhancing area (cold spot). Mean peak SIE in the nonischemic myocardium (posterior wall) was significantly higher than in the ischemic myocardium (anterior wall) (110 +/- 23% vs. 74 +/- 22%, Mann-Whitney test alpha < 1%, n(1) = 6, n(2) - n(1) = 0, U > 2). In conclusion, the T-1 effect of SPIOs at low dose, during their first intravascular distribution, suggests their potential use as positive markers to investigate the regional myocardial blood flow and some perfusion defects such as the ''no-reflow phenomenon.''
引用
收藏
页码:1139 / 1145
页数:7
相关论文
共 27 条
[1]  
Josephson, Lewis, Jacobs, Et al., The effects of iron oxides on proton relaxivity, Magn. Reson. Med., 6, pp. 647-653, (1988)
[2]  
Weissleder, Stark, Engelstad, Et al., Superparamagnetic iron oxide: Pharmacokinetics and toxicity, AJR, 152, pp. 167-173, (1989)
[3]  
Stark, Weissleder, Elizondo, Et al., Superparamagnetic iron oxide: Clinical application as a contrast agent for MR imaging of the liver, Radiology, 168, pp. 297-301, (1988)
[4]  
Marchal, Van Hecke, Demaerel, Et al., Detection of liver metastases with superparamagnetic iron oxide in 15 patients: Results of MR imaging at 1.5 T, AJR, 152, pp. 771-775, (1989)
[5]  
Majumdar, Zoghbi, Gore, Regional differences in rat brain displayed by fast MRI with superparamagnetic contrast agents, Magn. Reson. Imaging, 6, pp. 611-615, (1988)
[6]  
Gore, Majumdar, Measurement of tissue blood flow using intravascular relaxation agents and magnetic resonance imaging, Magn. Reson. Med., 14, pp. 242-248, (1990)
[7]  
Edelman, Siegel, Singer, Et al., Dynamic MR imaging of the liver with Gd-DTPA. Initial clinical results, AJR, 153, pp. 1213-1219, (1989)
[8]  
Atkinson, Burstein, Edelman, First pass cardiac perfusion: Evaluation with ultrafast MR imaging, Radiology, 174, pp. 757-762, (1990)
[9]  
Manning, Atkinson, Grossman, Paulin, Edelman, First pass nuclear magnetic resonance imaging studies using gadolinium-DTPA in patients with coronary artery deseases, J. Am. Coll. Cardiol., 18, pp. 959-965, (1991)
[10]  
Rosen, Belliveau, Buchbinder, Et al., Contrast agents and cerebral hemodynamics, Magn. Reson. Med., 19, pp. 285-292, (1991)